Clinical Trial Update: A First-in-human Study of 3HP-2827 in Patients With Unresectable or Metastatic Solid Tumors With FGFR2 Alterations [Phase 1]

View source ↗

Summary

This is a first-in-human Phase 1 trial of 3HP-2827 in adults with unresectable or metastatic solid tumors bearing FGFR2 alterations, and the study is not yet re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors with Fgfr2 Alterations

Drugs mentioned

• 3HP-2827 (3HP-2827)

Snippet

Sponsor: 3H (Suzhou) Pharmaceuticals Co., Ltd. | Conditions: Solid Tumors With FGFR2 Alterations, Adult | Phase 1 | Status: NOT_YET_RECRUITING